MiR130b from Schlafen4
Animals
Carrier Proteins
/ metabolism
Cell Transformation, Neoplastic
/ genetics
Disease Models, Animal
Gene Expression Regulation, Neoplastic
Helicobacter Infections
/ metabolism
Helicobacter pylori
/ physiology
Interferon-alpha
/ metabolism
Mice
Mice, Knockout
MicroRNAs
/ metabolism
Myeloid-Derived Suppressor Cells
/ metabolism
Precancerous Conditions
Stomach Neoplasms
/ metabolism
gastric cancer
gastric inflammation
gastric metaplasia
helicobacter felis
interferon-alpha
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
31
03
2019
revised:
26
12
2019
accepted:
09
01
2020
pubmed:
26
1
2020
medline:
10
4
2021
entrez:
26
1
2020
Statut:
ppublish
Résumé
The myeloid differentiation factor Schlafen4 (Slfn4) marks a subset of myeloid-derived suppressor cells (MDSCs) in the stomach during To identify the gene products expressed by Slfn4 We performed transcriptome analyses for both coding genes (mRNA by RNA-Seq) and non-coding genes (microRNAs using NanoString nCounter) using flow-sorted SLFN4 MicroRNA analysis identified an increase in MiR130b in gastric SLFN4 Taken together, MiR130b plays an essential role in MDSC function and supports metaplastic transformation.
Identifiants
pubmed: 31980446
pii: gutjnl-2019-318817
doi: 10.1136/gutjnl-2019-318817
pmc: PMC7377952
mid: NIHMS1565878
doi:
Substances chimiques
Carrier Proteins
0
Interferon-alpha
0
MIRN130 microRNA, mouse
0
MicroRNAs
0
schlafen-4 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1761Subventions
Organisme : NIDDK NIH HHS
ID : P01 DK062041
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034933
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK041301
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118563
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Surg Oncol. 2013 Apr;107(5):505-10
pubmed: 22996433
Invest Ophthalmol Vis Sci. 2013 Jul 26;54(7):5070-7
pubmed: 23812491
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Gastroenterology. 2010 Jun;138(7):2207-10, 2210.e1
pubmed: 20450866
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7
pubmed: 19346489
PLoS One. 2011 Jan 07;6(1):e15723
pubmed: 21249125
Brain Pathol. 2010 May;20(3):539-50
pubmed: 19775293
Oncogene. 2013 Jul 4;32(27):3286-95
pubmed: 22847613
Tumour Biol. 2016 Jun;37(6):7981-7
pubmed: 26711782
Oncotarget. 2016 Jul 26;7(30):48547-48561
pubmed: 27391066
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Neoplasia. 2013 Sep;15(9):1086-99
pubmed: 24027433
PLoS One. 2013;8(3):e58935
pubmed: 23520544
Oncotarget. 2016 Jul 12;7(28):44522-44533
pubmed: 27304191
PLoS One. 2012;7(5):e35661
pubmed: 22623952
Sci Rep. 2017 Feb 06;7:41942
pubmed: 28165066
Int J Mol Sci. 2016 Dec 31;18(1):
pubmed: 28042869
Methods Mol Biol. 2019;1576:205-213
pubmed: 27539460
Immunology. 2013 Feb;138(2):105-15
pubmed: 23216602
J Clin Invest. 2016 Aug 1;126(8):2867-80
pubmed: 27427984
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Int Immunol. 2004 Oct;16(10):1535-48
pubmed: 15351786
Cell Stem Cell. 2010 Dec 3;7(6):694-707
pubmed: 21112564
Oncol Rep. 2017 Jul;38(1):167-174
pubmed: 28534976
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):186-92
pubmed: 23325475
PLoS One. 2013 Sep 10;8(9):e73803
pubmed: 24040078
Blood. 2003 Feb 15;101(4):1316-23
pubmed: 12406876
J Cell Physiol. 2014 May;229(5):631-9
pubmed: 24311275
Eur J Cancer. 2010 May;46(8):1456-63
pubmed: 20176475
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143
pubmed: 28918016
BMJ Open. 2012 Mar 08;2(2):e000825
pubmed: 22403344